Silodosin

alpha-Adrenergic Blocker — GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Silodosin is an ofp drug in the alpha-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2008. Its mechanism of action is classified as Adrenergic alpha-Antagonists. DrugCentral lists 19 molecular targets, including ADRA1A, Adra1a and ADRA1D. Recorded indications include Benign prostatic hyperplasia.

• Approval status: ofp (first approved 2008 by the FDA).
• Drug class: alpha-Adrenergic Blocker.
• Mechanism of action: Adrenergic alpha-Antagonists.
• Molecular targets: ADRA1A, Adra1a, ADRA1D and ADRA1B (19 listed in DrugCentral).
• Indications: Benign prostatic hyperplasia.
• ATC code: G04CA04 (Alpha-adrenoreceptor antagonists).
• Molecular formula: C25H32F3N3O4; molecular weight 495.54 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Benign prostatic hyperplasia

Contraindications (6)

• Acute nephropathy
• Cataract surgery
• Hepatic failure
• Intraoperative floppy iris syndrome
• Kidney disease
• Orthostatic hypotension

Mechanism & targets

• Mechanism of action (MoA): Adrenergic alpha-Antagonists
• Established pharmacologic class: alpha-Adrenergic Blocker

Molecular targets (19)

Target	Gene	Action	Activity
Alpha-1A adrenergic receptor	ADRA1A	antagonist	Ki 10.44
Alpha-1A adrenergic receptor	Adra1a	unknown	IC50 9.10
Alpha-1D adrenergic receptor	ADRA1D	antagonist	Ki 8.70
Alpha-1B adrenergic receptor	ADRA1B	antagonist	Ki 7.70
Beta-2 adrenergic receptor	ADRB2	unknown	Ki 7.48
5-hydroxytryptamine receptor 1A	HTR1A	unknown	Ki 7.33
D(3) dopamine receptor	DRD3	unknown	Ki 7.14
5-hydroxytryptamine receptor 1D	HTR1D	unknown	Ki 7.04
Alpha-2C adrenergic receptor	ADRA2C	unknown	Ki 6.44
5-hydroxytryptamine receptor 1B	HTR1B	unknown	Ki 6.43
5-hydroxytryptamine receptor 7	HTR7	unknown	Ki 6.32
Alpha-2A adrenergic receptor	ADRA2A	unknown	Ki 6.17
Alpha-2B adrenergic receptor	ADRA2B	unknown	Ki 6.11
D(2) dopamine receptor	DRD2	unknown	Ki 6.00
D(4) dopamine receptor	DRD4	unknown	Ki 5.80
5-hydroxytryptamine receptor 2B	HTR2B	unknown	Ki 5.68
Histamine H1 receptor	HRH1	unknown	Ki 5.45
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	IC50 5.09
Multidrug resistance protein 1	ABCB1	unknown	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2010-01-29	EMA	—	—
2008-10-08	FDA	—	ACTAVIS LABS UT INC

ATC classification

ATC code	Therapeutic hierarchy
G04CA04	GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Urinary retention	243.6
Reversible airways obstruction	140.9
Acute kidney injury	134.5
Interstitial lung disease	130.0
Hyponatraemia	90.9
Erectile dysfunction	89.2
Cerebral infarction	79.6
Retrograde ejaculation	72.3
Inappropriate antidiuretic hormone secretion	68.9
Haematuria	68.4
Granulomatous rosacea	67.1
Orthostatic hypotension	64.2

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Silodosin is on its molecule page.

• Molecular formula: C₂₅H₃₂F₃N₃O₄
• Molecular weight: 495.54 g/mol
• CAS number: 160970-54-7
• InChIKey: PNCPYILNMDWPEY-QGZVFWFLSA-N
• PubChem CID: 5312125

C[C@H](CC1=CC2=C(N(CCCO)CC2)C(=C1)C(N)=O)NCCOC1=CC=CC=C1OCC(F)(F)F

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Silodosin used for?

DrugCentral lists the following indications for Silodosin: Benign prostatic hyperplasia.

How does Silodosin work?

Silodosin is classified as Adrenergic alpha-Antagonists; its molecular targets in DrugCentral include ADRA1A (antagonist), Adra1a, ADRA1D (antagonist) and ADRA1B (antagonist).

When was Silodosin first approved?

Silodosin was first approved by the FDA in 2008.

What drug class does Silodosin belong to?

Silodosin is in the alpha-Adrenergic Blocker class.

What is the chemical formula of Silodosin?

Silodosin has the molecular formula C25H32F3N3O4 and a molecular weight of 495.54 g/mol.

Sources

• DrugCentral drug card 4151 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL24778 — compound record and bioactivity
• PubChem CID 5312125 — chemical identifiers
• DrugBank DB06207 — drug record
• FDA UNII CUZ39LUY82 — substance identity
• DailyMed: FDA labels for Silodosin — current prescribing information (label search)
• UniProt P35348 (ADRA1A) — target protein
• UniProt P25100 (ADRA1D) — target protein
• UniProt P35368 (ADRA1B) — target protein
• UniProt P07550 (ADRB2) — target protein
• UniProt P08908 (HTR1A) — target protein
• UniProt P35462 (DRD3) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.